OncoMatch/Clinical Trials/NCT05359445
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Is NCT05359445 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including IMA401 (Phase Ia) and Pembrolizumab (Phase Ia) for refractory cancer.
Treatment: IMA401 (Phase Ia) · Pembrolizumab (Phase Ia) · IMA 401 (Phase Ib) — The goal of this clinical trial is to evaluate the safety, tolerability and initial anti-tumor activity of IMA401 as monotherapy or in combination with checkpoint inhibitor in patients with recurrent and/or refractory solid tumors. Patients' HLA status and expression of the MAGE-A4 and/or MAGE-A8 target in the tumor must be confirmed. Primary objective: * To determine the maximum tolerated dose and/or recommended dose for extension for IMA401 as monotherapy and in combination with pembrolizumab Secondary objectives: * To characterize the safety and tolerability of IMA401 as monotherapy and in combination with pembrolizumab * To evaluate initial anti-tumor activity of IMA401 as monotherapy and in combination with pembrolizumab * To describe the pharmacokinetics of IMA401 as monotherapy and in combination with pembrolizumab
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: MAGEA4 expression
Required: MAGEA8 expression
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate baseline hematologic function
Kidney function
adequate baseline renal function
Liver function
adequate baseline hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify